Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Betalutin in Relapsed Non-Hodgkin Lymphoma
NCT01796171Phase 2Completed
- Sponsor
- Nordic Nanovector ASA
- Start
- Dec 2012
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 24
01
Overview
A Phase 2 trial of lutetium (177Lu) lilotomab satetraxetan in non-Hodgkin lymphoma (NHL), follicular lymphoma (FL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), small lymphocytic lymphoma (SLL), sponsored by Nordic Nanovector ASA. Started Dec 2012; status: completed.
02
Drugs
lutetium (177Lu) lilotomab satetraxetan
03
Conditions
non-Hodgkin lymphoma (NHL)follicular lymphoma (FL)marginal zone lymphoma (MZL)mantle cell lymphoma (MCL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT01796171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01796171.